<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The clinical and haematological findings in 131 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), none of which had previously received chemotherapy or radiotherapy, classified according to the FAB criteria, were analysed </plain></SENT>
<SENT sid="1" pm="."><plain>The distribution among the 5 subgroups was: RA 31 patients, <z:mp ids='MP_0011356'>RAS</z:mp> 19, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> 23, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> 29 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEBT</z:e> 29 patients </plain></SENT>
<SENT sid="2" pm="."><plain>There were difficulties in the classification of 24 patients </plain></SENT>
<SENT sid="3" pm="."><plain>These included, first, 8 cases with <z:mp ids='MP_0010373'>myeloid hyperplasia</z:mp> of the bone marrow (BM) but without <z:mp ids='MP_0000220'>monocytosis</z:mp> or excess of blasts of the BM </plain></SENT>
<SENT sid="4" pm="."><plain>They were classified as RA </plain></SENT>
<SENT sid="5" pm="."><plain>Second, 8 cases with <z:e sem="disease" ids="C0679425" disease_type="Disease or Syndrome" abbrv="">sideroblastosis</z:e> but with <z:mp ids='MP_0000220'>monocytosis</z:mp> or excess of blasts of the BM were classified 3 as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 2 as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and 3 as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEBT</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Finally, 8 cases with absolute <z:mp ids='MP_0000220'>monocytosis</z:mp> and BM blasts 15-30% were classified as <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>37 of 82 dead patients (45.1%) had transformed to <z:hpo ids='HP_0011009'>acute</z:hpo> non-lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ANLL) </plain></SENT>
<SENT sid="8" pm="."><plain>The incidence of evolution to ANLL was low for RA and <z:mp ids='MP_0011356'>RAS</z:mp> (6.30% and 12.5% respectively), while it was 37.5% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, 57.1% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> and 77.2% for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEBT</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The median survival for each subgroup was: RA 18 months; <z:mp ids='MP_0011356'>RAS</z:mp> 25; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> 13; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> 14 and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEBT</z:e> 10 months </plain></SENT>
<SENT sid="10" pm="."><plain>It is concluded that the FAB classification with some modifications recognises group of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with different prognosis </plain></SENT>
</text></document>